Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
New study shows how immune system developed in the course of evolution

New study shows how immune system developed in the course of evolution

Scientists at the Max Planck Institute of Immunobiology and Epigenetics (MPI-IE) in Freiburg re-activated expression of an ancient gene, which is not normally expressed in the mammalian immune system, and found that the animals developed a fish-like thymus. [More]
Natural killer cells can be used to combat acute lymphoblastic leukemia

Natural killer cells can be used to combat acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that can be used to destroy the cancer cells. [More]
Complete analysis of bioseparation technologies for global biopharmaceutical markets

Complete analysis of bioseparation technologies for global biopharmaceutical markets

Reportlinker.com announces that a new market research report is available in its catalogue: ​Bioseparation Systems for Global Biopharmaceutical Markets [More]
Anti-EphA3 antibody has anti-tumour effects against solid cancers

Anti-EphA3 antibody has anti-tumour effects against solid cancers

An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumour effects. [More]
Food allergies more common in young inner-city children

Food allergies more common in young inner-city children

Already known for their higher-than-usual risk of asthma and environmental allergies, young inner-city children appear to suffer disproportionately from food allergies as well, according to results of a study led by scientists at the Johns Hopkins Children’s Center. [More]
Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Babies suffering from life-threatening bacterial infections such as sepsis could benefit from improved treatment, thanks to a ground-breaking study. [More]
Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons, which amplify the immune system response to viruses. [More]
High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine. [More]
Lung-damaging bacterium turns body's antibody response in its favor

Lung-damaging bacterium turns body's antibody response in its favor

A lung-damaging bacterium turns the body's antibody response in its favor, according to a study published in The Journal of Experimental Medicine. [More]
Researchers develop novel fluorescence-based assay for early detection of diabetes

Researchers develop novel fluorescence-based assay for early detection of diabetes

A team of researchers from the Center for Engineering in Medicine at the Massachusetts General Hospital have developed a novel fluorescence-based assay for sensitive detection of antibodies within microliter volume serum samples. [More]
OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy announced today that the FDA Office of Orphan Products Development has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor. [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Seven physicians receive ASTRO grants to advance radiation oncology research

Seven physicians receive ASTRO grants to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology. [More]
Complete analysis of the growing manufacturing market of HPAPIs and cytotoxic drugs

Complete analysis of the growing manufacturing market of HPAPIs and cytotoxic drugs

Reportbuyer.com has added a new market research report: HPAPIs and Cytotoxic Drugs Manufacturing Market, 2014 - 2024 [More]
Injecting vaccine-like compound into mice effective in protecting from malaria

Injecting vaccine-like compound into mice effective in protecting from malaria

A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine-like compound into mice was effective in protecting them from malaria. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Patient with mechanical heart pump receives new gene therapy for heart failure

Patient with mechanical heart pump receives new gene therapy for heart failure

For the first time in the world, a patient with a mechanical heart pump has received a new gene therapy for heart failure at Harefield Hospital, London. [More]
Researchers find that animal's ability to endure internal parasite strongly influences reproductive success

Researchers find that animal's ability to endure internal parasite strongly influences reproductive success

In the first evidence that natural selection favors an individual's infection tolerance, researchers from Princeton University and the University of Edinburgh have found that an animal's ability to endure an internal parasite strongly influences its reproductive success. [More]
3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey). [More]
Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™. [More]